These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31868223)

  • 41. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.
    Wang X; Cerrone M; Ferretti F; Castrillo N; Maartens G; McClure M; Boffito M
    Int J Antimicrob Agents; 2019 Aug; 54(2):202-206. PubMed ID: 31002950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.
    Singh RP; Adkison KK; Baker M; Parasrampuria R; Wolstenholme A; Davies M; Sewell N; Brothers C; Buchanan AM
    Pediatr Infect Dis J; 2022 Mar; 41(3):230-237. PubMed ID: 34817414
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.
    De Sousa Mendes M; Hirt D; Vinot C; Valade E; Lui G; Pressiat C; Bouazza N; Foissac F; Blanche S; Lê MP; Peytavin G; Treluyer JM; Urien S; Benaboud S
    Br J Clin Pharmacol; 2016 Apr; 81(4):646-57. PubMed ID: 26518984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition.
    Elliot ER; Wang X; Singh S; Simmons B; Vera JH; Miller RF; Fitzpatrick C; Moyle G; McClure M; Boffito M
    Clin Infect Dis; 2019 Jan; 68(1):87-95. PubMed ID: 29771285
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir.
    Liu XI; Momper JD; Rakhmanina NY; Green DJ; Burckart GJ; Cressey TR; Mirochnick M; Best BM; van den Anker JN; Dallmann A
    Clin Pharmacokinet; 2021 Jun; 60(6):795-809. PubMed ID: 33527213
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions.
    Enoki Y; Kishi N; Sakamoto K; Uchiyama E; Hayashi Y; Suzuki N; Ito M; Taguchi K; Yokoyama Y; Kizu J; Matsumoto K
    Drug Metab Pharmacokinet; 2021 Apr; 37():100371. PubMed ID: 33556698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.
    Bunglawala F; Rajoli RKR; Mirochnick M; Owen A; Siccardi M
    J Antimicrob Chemother; 2020 Mar; 75(3):640-647. PubMed ID: 31860112
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial.
    Bevers LAH; Waalewijn H; Szubert AJ; Chabala C; Bwakura-Dangarembizi M; Makumbi S; Nangiya J; Mumbiro V; Mulenga V; Musiime V; Burger DM; Gibb DM; Colbers A
    Clin Infect Dis; 2023 Nov; 77(9):1312-1317. PubMed ID: 37280040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of Various Approaches to Estimate Transplacental Clearance of Vancomycin for Predicting Fetal Concentrations using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
    Yan Y; Wang Q; Wu W; Yi H; Xie F
    Pharm Res; 2024 May; 41(5):899-910. PubMed ID: 38684563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimization of the betamethasone and dexamethasone dosing regimen during pregnancy: a combined placenta perfusion and pregnancy physiologically based pharmacokinetic modeling approach.
    Van Der Heijden JEM; Van Hove H; Van Elst NM; Van Den Broek P; Van Drongelen J; Scheepers HCJ; De Wildt SN; Greupink R
    Am J Obstet Gynecol; 2024 May; ():. PubMed ID: 38763343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
    Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
    PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.
    Min S; Song I; Borland J; Chen S; Lou Y; Fujiwara T; Piscitelli SC
    Antimicrob Agents Chemother; 2010 Jan; 54(1):254-8. PubMed ID: 19884365
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
    Yamada E; Takagi R; Moro H; Sudo K; Kato S
    PLoS One; 2021; 16(2):e0246994. PubMed ID: 33600473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dolutegravir Population Pharmacokinetics in a Real-Life Cohort of People Living With HIV Infection: A Covariate Analysis.
    Parant F; Miailhes P; Brunel F; Gagnieu MC
    Ther Drug Monit; 2019 Aug; 41(4):444-451. PubMed ID: 30817698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
    Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S
    Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predicting fetal exposure of crizotinib during pregnancy: Combining human ex vivo placenta perfusion data with physiologically-based pharmacokinetic modeling.
    Roelofsen D; van Hove H; Bukkems V; Russel F; Eliesen G; Greupink R
    Toxicol In Vitro; 2022 Dec; 85():105471. PubMed ID: 36096459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of Maternal and Fetoplacental Concentrations of Cefazolin, Cefuroxime, and Amoxicillin during Pregnancy Using Bottom-Up Physiologically Based Pharmacokinetic Models.
    Abduljalil K; Ning J; Pansari A; Pan X; Jamei M
    Drug Metab Dispos; 2022 Apr; 50(4):386-400. PubMed ID: 35046066
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
    Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.
    Liu XI; Momper JD; Rakhmanina N; van den Anker JN; Green DJ; Burckart GJ; Best BM; Mirochnick M; Capparelli EV; Dallmann A
    J Clin Pharmacol; 2020 Feb; 60(2):240-255. PubMed ID: 31489678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.